TX-DAVE-&-BUSTER'S
1.4.2024 15:01:28 CEST | Business Wire | Press release
Dave & Buster's Entertainment, Inc, Dave & Buster’s the ultimate destination for food, drink and entertainment is proud to announce its continued international expansion with a pivotal franchise agreement. Positioned to extend its global presence, Dave & Buster’s has finalized a deal to open two locations in the Dominican Republic, elevating the total to 33 stores slated for international development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240401479317/en/
Dave & Buster's Entertainment, Inc (Photo: Business Wire)
Antonio Bautista, Chief International Development Officer at Dave & Buster’s, shared his excitement about entering the market. "We are delighted to announce our expansion into the Dominican Republic, marking a noteworthy milestone in our global growth strategy. Dave & Buster's is set to make a significant impact by partnering with Grupo Pais, aimed at revolutionizing the local entertainment and hospitality landscape. The vibrant market of the Dominican Republic presents a fantastic opportunity for us to bring the unique Dave & Buster's experience to new guests," said Bautista. "Our partnership with Grupo Pais, known for its innovative and consumer-first approach, will allow us to set a new standard for entertainment in the region."
Juan Carlos Pais, CEO of Grupo Pais, commented on the new venture, “We are thrilled to introduce Dave & Buster's to the Dominican Republic. The brand's commitment to providing an unmatched combination of entertainment and dining fits perfectly with our market's demand for innovative experiences. This partnership promises to redefine entertainment in our country."
Dave & Buster's has implemented several strategic initiatives to ensure a successful global expansion, including a customizable footprint tailored to meet specific market requirements and the localization of menu offerings with high regional resonance to cater to local preferences and tastes. They have also introduced a proprietary dynamic pricing model to offer flexible pricing options, launched global marketing programs that are demographically agnostic yet locally executable, and implemented a unique amusement strategy and packages to differentiate themselves in the market.
Dave & Buster's is also excited to offer localized entertainment and late-night programming for customers and introduce immersive experiences to enhance customer engagement in the competitive socializing space. With these initiatives, Dave & Buster's is confident they will provide an exceptional experience to their global customers.
About Dave & Buster’s
Founded in 1982 and headquartered in Coppell, Texas, Dave & Buster's Entertainment, Inc., is the owner and operator of 222 venues in North America that offer premier entertainment and dining experiences to guests through two distinct brands: Dave & Buster’s and Main Event. The Company has 163 Dave & Buster’s branded stores in 42 states, Puerto Rico, and Canada and offers guests the opportunity to "Eat Drink Play and Watch," all in one location. Each store offers a full menu of entrées and appetizers, a complete selection of alcoholic and non-alcoholic beverages, and an extensive assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The Company also operates 59 Main Event branded stores in 20 states across the country, and offers state-of-the-art bowling, laser tag, hundreds of arcade games and virtual reality, making it the perfect place for families to connect and make memories. For more information about each brand, visit daveandbusters.com and mainevent.com.
About Grupo Pais
GRUPO PAIS is a corporate conglomerate of retail, real estate, energy, services and commercial companies with more than 30 years of experience satisfying varied need-sets in the Dominican market. Its focus on product quality and service excellence, as well as its highly qualified partners, allow Grupo Pais to achieve optimal performance in the different segments in which they operate. Grupo Pais has successfully ventured into diverse markets through the operation and representation of internationally prestigious franchises, as well as important operations in the real estate, commercial, services and energy sectors. Grupo Pais’ vast experience in the affordable luxury, food, and beverage retail markets since 2008, has allowed its strategic positioning and presence in all main shopping centers of the Dominican Republic. The success achieved by Grupo Pais has prompted it to grow its presence at a regional level and expand its business category in the region. For more information about each brand, visit www.pais.do.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401479317/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom